UBS Lifts Halma Price Target to 4,000p After Guidance Upgrade

Halma (LON: HLMA) shares gained 1% on Thursday after UBS raised its price target on the life sciences and safety technology group to 4,000p from 3,730p, reiterating a Buy rating.

UBS analyst Andre Kukhnin said the increase reflects Halma’s upgraded organic growth guidance following its latest trading update.

“We view this as another very strong print by Halma and continue to see an attractive compounding growth investment case in Halma, and hence reiterate our Buy rating,” stated UBS.

Halma shares have performed strongly this year, rising more than 25% year to date. Thursday saw the stock climb as high as 3,444p before it closed 1% higher at 3,372p per share. So far on Friday, it is down around 0.2% at 3,366p.

The stock’s momentum has been fuelled by optimism around its growth strategy and its positioning in structurally attractive markets, including environmental monitoring and healthcare technology.

Recent broker moves have underlined the positive sentiment. Earlier this month, Deutsche Bank lifted its price target to 3,290p, though it maintained a Hold rating, while Goldman Sachs initiated coverage in August with a Buy rating and a 3,740p target, citing Halma’s sustainable high-growth, high-returns model.

According to TradingView data, nine analysts currently rate Halma a Buy, six a Hold and one a Sell, with a consensus target of 3,412p, below UBS’s new 4,000p level.